Medco: Follow-on biotech drugs could drive market growth

11/23/2008 | Reuters

Medco Health Solutions told investors Friday that follow-on biotech medicines could help the company and its customers save money if a regulatory pathway for such products is created. Assuming that an approval process would start in 2011, Amgen's Aranesp, Genentech's Avastin and Johnson & Johnson's Remicade would be among top-selling drugs that may face follow-on competition between 2013 and 2017, Medco said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY